Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, Virginia, USA.
Department of Pulmonary Medicine, Vrije Universiteit (VU) Medical Center, Amsterdam, Netherlands.
Pulm Circ. 2015 Mar;5(1):81-9. doi: 10.1086/679702.
For many patients with severe pulmonary arterial hypertension, heart failure-and, in particular, right heart failure-is the final chapter of their chronic illness. Targeted therapy for pulmonary hypertension is effective only if the right ventricular ejection fraction is maintained or improved. Because improvement of right heart function and reversal of right heart failure are treatment goals, it is important to investigate the cellular and molecular mechanisms that cause right heart failure. Here, we propose that right ventricular capillary rarefaction is an important hallmark of right heart failure and consider that the "sick lung circulation" and the pressure-overloaded right ventricle constitute a functional unit.
对于许多患有严重肺动脉高压的患者来说,心力衰竭——尤其是右心衰竭——是他们慢性疾病的最后一章。肺动脉高压的靶向治疗只有在维持或改善右心室射血分数的情况下才有效。由于改善右心功能和逆转右心衰竭是治疗目标,因此研究导致右心衰竭的细胞和分子机制非常重要。在这里,我们提出右心室毛细血管稀疏是右心衰竭的一个重要标志,并认为“病态肺循环”和压力超负荷的右心室构成一个功能单元。